{"denoms":[{"counts":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"127"}],"units":"Participants"}],"groups":[{"description":"All subjects randomized to receive sipuleucel-T. Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.","id":"BG000","title":"Sipuleucel-T"},{"description":"All subjects randomized to receive placebo. Approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.1","value":"72.1"},{"groupId":"BG001","spread":"8.3","value":"71.1"},{"groupId":"BG002","spread":"8.1","value":"71.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"47","upperLimit":"85","value":"73.0"},{"groupId":"BG001","lowerLimit":"50","upperLimit":"86","value":"71.0"},{"groupId":"BG002","lowerLimit":"47","upperLimit":"86","value":"73.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"Years (Min, Max)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"127"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}